Best in Biotech 7 Mar 2024 6 biotech companies tackling antibiotic resistance …– expected in the first quarter of 2025. Clarametyx Biosciences Launched in 2020 to advance a novel, immune-enabling antibody technology licensed from Nationwide Children’s Hospital, Clarametyx Biosciences is combating persistent… March 7, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing …provide the contours of what might be possible: sustained antibody responses and LDL-lowering signals in preclinical models and non-human primates, with modest human signals so far for AT04A and ongoing… October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Feb 2020 This Startup is Developing Anti-Aging Antibodies The Heidelberg-based startup Velabs Therapeutics aims to make anti-aging drugs that selectively destroy ‘aged’ cells in the body. Mission: To develop antibody drugs using microfluidics technology that can kill old… February 21, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2018 Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls…. November 27, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2022 Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials …Gilead Sciences’ remdesivir. In November and December, several antibody drugs were greenlit, including regdanvimab developed by the South Korean company Celltrion and sotrovimab, marketed by GSK. However, the rise of… February 15, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Nov 2024 From consumer health to pure biopharma: Inside Sanofi’s strategic shift …as ANB033 (anti-CD122 antagonist antibody) entering a phase 1 trial, and ANB101 (BDCA2 modulator antibody) in preclinical development. Moreover, just after it announced it wanted to separate its consumer health… November 5, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 11 Nov 2019 Mereo BioPharma’s Brittle Bone Disease Drug Stumbles in Phase II …bone disease. Mereo tested different doses of its antibody drug in 112 adults with osteogenesis imperfecta in a 12-month phase IIb trial. The drug failed to meet the main endpoint… November 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Disc Medicine raises $62.5M for hematology programs …DISC-0974 (hepcidin suppression) is another treatment in the pipeline. It is a first-in-class, investigational, anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin production and increase serum iron to enable erythropoiesis…. February 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Apr 2024 Chicago biotech: Seven players advancing the industry …is a biopharmaceutical company focused on developing therapies that target senescent cells and cancer. Their leading compound, SIWA318H, is an antibody that targets advanced glycation end products (AGEs), which are… April 2, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Aug 2024 Seven companies transforming the biotech industry in Italy …Among them is a vaccine for malaria, which has received significant attention and funding, including $12.2 million from the EU Malaria Fund. Another prominent candidate is MAbCo19, a monoclonal antibody… August 22, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer Regeneron and Sanofi have announced positive early results from a Phase II study investigating their skin cancer antibody, cemiplimab. Despite deciding to end their antibody partnership at the end of… December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 27 Mar 2017 Meet one of the Most Successful Biotech Entrepreneurs in the UK …Molecular Genetics at Leicester, and then a postdoc at Bath on antibody engineering, before moving to Cambridge to work at the GURDON Institute. It was during his postdoc and his… March 27, 2017 - 7 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email